# A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination

> **NCT06448364** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 4 (actual)

## Conditions studied

- Advanced or Metastatic Solid Tumors
- Non-Small Cell Lung Cancer
- Colorectal Cancer
- Urothelial Cancer
- Melanoma

## Interventions

- **BIOLOGICAL:** PF-07329640
- **BIOLOGICAL:** sasanlimab
- **BIOLOGICAL:** bevacizumab

## Key facts

- **NCT ID:** NCT06448364
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-05-09
- **Primary completion:** 2024-08-15
- **Final completion:** 2024-08-15
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Strategic business decision
- **Last updated:** 2024-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06448364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06448364, "A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06448364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*